What 2025 reviews actually added about BPC-157
Two independent 2025 reviews mapped hundreds of papers and still found almost no controlled human data.
Two reviews published in 2025 asked the same question from different angles: after decades of rodent papers, what can anyone honestly say about BPC-157 in people?
The orthopaedic systematic review
Vasireddi and colleagues screened 544 records through June 2024 and kept 36 studies: 35 preclinical and one clinical. The lone human paper was a retrospective series of 12 people given an intra-articular injection for unspecified chronic knee pain; 7 said they felt better for more than six months. There was no control group. The reviewers found no clinical safety data.
The musculoskeletal narrative review
A second 2025 review, searching through March 2025, described proposed mechanisms — VEGF/VEGFR2 signalling, nitric-oxide pathways, and effects on poorly vascularized tendon — and counted only three small human pilots (knee pain, interstitial cystitis, and a tiny intravenous pharmacokinetics study). No randomized musculoskeletal trial was identified.
What that means
Animal models still suggest effects on tendon, muscle and bone healing. That is a reason to run controlled human trials, not evidence that a research-chemical vial heals sports injuries. BPC-157 remains not FDA-approved and is prohibited in sport.
Bottom line
Evidence ladder: Animal. The 2025 reviews did not upgrade the human evidence. They documented how thin it still is.
Sources
Educational content only — not medical advice. See our Medical disclaimer and Editorial policy.